i just hope and pray they don't go down the path that ANP did...
it had so much potential and excitement around it with a key trial to commence and then management did a bloodbath placing that only supported the management and institutions. it probably also slowed down the process of getting the treatment to the kids.
very sad for the kids and very disappointing for shareholders (i am one of those).
you have so many junior biotech management going down the "lone rider" path (meaning no partnerships, deals etc..); it rarely works, takes longer and leads to massive dilution. all the talk about owning the treatment 100% is BS, since it's then so far down the road linked to so much dilution that it's ridiculous to even use it as an argument.
so i really hope that Recce management can show that they are more professional than the average biotech executive...
RCE Price at posting:
$1.21 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)